search
Back to results

Study on Effective Mydriasis in Premature Infants

Primary Purpose

Retinopathy of Prematurity (ROP)

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
1% phenylephrine and 0.2% cyclopentolate
Sponsored by
Georgetown University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Retinopathy of Prematurity (ROP) focused on measuring Retinopathy of Prematurity (ROP), Eye exams, Premature infants, cyclomydril

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Premature infants undergoing clinically indicated retinal exams

Exclusion Criteria:

  • Ocular congenital anomalies
  • Pre-threshold ROP

Sites / Locations

  • Georgetown University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

0 Drop

1 Drop

2 drop

3 drops

Arm Description

Left eye dose

Left eye dose

Left eye dose

Right eye dose for all groups

Outcomes

Primary Outcome Measures

dilation of the pupil in millimeters

Secondary Outcome Measures

Full Information

First Posted
January 21, 2010
Last Updated
January 21, 2010
Sponsor
Georgetown University
search

1. Study Identification

Unique Protocol Identification Number
NCT01054027
Brief Title
Study on Effective Mydriasis in Premature Infants
Official Title
A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants
Study Type
Interventional

2. Study Status

Record Verification Date
January 2010
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
March 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Georgetown University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the dilating effect of 0, 1, 2 or 3 drops of mydriatic (pupil dilating) in premature infants undergoing routine retinal (eye) screening exams for Retinopathy of Prematurity (ROP).
Detailed Description
Premature infants need to have eye exams starting at about 4 weeks of age and continuing until their retinas (membrane at the back of the eye which collects and transfers light) is fully grown. These exams are done to see if they have developed ROP, a disease which can lead to blindness if not treated. The ophthalmologist (eye doctor) looks through the enlarged pupil (opening at the front of the eye) to see the retina. The drug that is used to dilate the pupil, Cyclomydril, has been shown to have side effects in premature infants. No literature has shown what the optimal dose is for premature babies. Nursery policy is to give 3 drops of Cyclomydril in each eye, at 5 minute intervals, 45-60 minutes before a scheduled eye exam. We sought to reduce the dose without delaying the exam for an under-sized pupil. In the study, each infant is randomized at the time of the exam to receive either 0, 1 or 2 drops of Cyclomydril in the left eye and 3 drops in the right eye to serve as their own control. The zero-drop group was created to test the contralateral (opposite eye) effect of 3 drops in the right eye. Pupil dilation size is measured using the Colvard pupillometer by a Pediatric Ophthalmologist examiner (G.V.V.) who was not masked to study group assignment. Measures of pupil size are done at baseline (before any drops given), 45, 90 and 120 minutes after the first drop was given. ROP screening exam is done at the first opportunity to visualize the posterior and peripheral retina. Additional drops are given at 120 minutes if the observer is unable to complete the exam prior to that point.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinopathy of Prematurity (ROP)
Keywords
Retinopathy of Prematurity (ROP), Eye exams, Premature infants, cyclomydril

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
0 Drop
Arm Type
Experimental
Arm Description
Left eye dose
Arm Title
1 Drop
Arm Type
Experimental
Arm Description
Left eye dose
Arm Title
2 drop
Arm Type
Experimental
Arm Description
Left eye dose
Arm Title
3 drops
Arm Type
Active Comparator
Arm Description
Right eye dose for all groups
Intervention Type
Drug
Intervention Name(s)
1% phenylephrine and 0.2% cyclopentolate
Other Intervention Name(s)
Cyclomydril
Intervention Description
given as drops, prior to eye exam
Primary Outcome Measure Information:
Title
dilation of the pupil in millimeters
Time Frame
at baseline (no drops yet instilled), 45, 90 and 120 minutes after drops instilled

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Premature infants undergoing clinically indicated retinal exams Exclusion Criteria: Ocular congenital anomalies Pre-threshold ROP
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Monisha Bahri, MD
Organizational Affiliation
Georgetown University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Georgetown University Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study on Effective Mydriasis in Premature Infants

We'll reach out to this number within 24 hrs